News

FDA Approves Lenvima for Thyroid Cancer based on SELECT results

A large, multi-center phase 3 study (SELECT trial) has found that patients with progressive, iodine refractory differentiated thyroid cancer have markedly improved progression free survival (PFS) when treated with lenvatinib, an oral tyrosine kinase inhibitor. Multiple ITOG members participated in the study, including lead author, Dr. Martin Schlumberger and senior author, Dr. Steven I. Sherman, current Chairman of ITOG.  The study, funded by the Eisai, the manufacturer of lenvatinib, was published in the New England Journal of Medicine, on February 12, 2015. On February 13th the FDA... Continue reading

ITOG Trial #1 Completes Enrollment

The first clinical trial initiated by ITOG in the fall of 2013 has completed its planned enrollment, marking a major accomplishment for ITOG.  The goal of this multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University, is to examine whether patients who had progression of their thyroid cancer on a VEGFR inhibitor benefit from treatment with cabozantinib. 

 This investigator-initiated clinical trial is truly a collaborative endeavor and every site has participated actively in the process. These efforts have facilitated an impressive timeline in which it took... Continue reading

Fall 2014 Newsletter

The 2014 Fall newsletter is here with important updates on our Selumetinib clinical trial, the Ruane Family's invovlement in ITOG, an update on the Annual Meeting, affiliation with the European Organization for Research and Treatment of Cancer (EORTC), updates on the Cabozantinib clinical trial, and a remembrance of Rick Abrams.  See the full newsletter in PDF by following this link: http://goo.gl/JMDrWP

ITOG Investigators Identify Novel Mutations in Thyroid Cancers That Could Lead to New Therapies

Recent publications from the laboratories of three separate ITOG members have reported the presence of a new type of mutation in certain thyroid cancers that could lead to use of specific use of certain drugs targeting that genetic abnormality.  Mutations in the gene ALK have previously been identified in certain lymphomas and types of lung cancer, and patients whose tumors harbor those mutations have often responded well to therapy with ALK inhibitors such as crizotinib.  Generally, these mutations are rearrangements of DNA, bringing parts of two genes together to create an active new gene... Continue reading

Update on ITOG’s First Clinical Trial

ITOG's first clinical trial has reached 50% of patient accrual. This multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University,examines whether patients who had progression of their thyroid cancer on a VEGFR inhibitor benefit from treatment with Cabozantinib. ITOG opened its first clinical trial one year ago for treatment of differentiated thyroid cancer.  NCI9312/OSU12154/RU241210I is an investigator-initiated, multicenter, open label, phase II trial of Cabozantinib in patients with radioiodine-refractory, differentiated thyroid cancer (DTC), who progressed on... Continue reading

Lenvatinib Extends PFS in Differentiated Thyroid Cancer

The phase III SELECT trial of the investigational agent lenvatinib (E7080) met its primary endpoint of progression-free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC), according to Eisai Inc., the company that is developing the agent.The trial compared lenvatinib to placebo and demonstrated a statistically significant improvement in PFS, which Eisai plans to submit for marketing authorization in the United States, Japan, and Europe, the company said in a statement. In a phase II study of Lenvatinib, a selective inhibitor of VEGFR 1-3, FGFR 1-4,... Continue reading

ITOG Members Participate in New York Masters Course in Endocrine Surgery

ITOG is pleased to report that four ITOG members will be moderators and/or panelists in the 2nd Annual New York Masters Course in Endocrine Surgery, December 6-7 at Icahn School of Medicine at Mount Sinai, New York, New York. The course will be an intensive review of key endocrine surgery topics, with special focus on current trends and techniques. This will include viewing live demonstrations of minimally invasive surgery for thyroidectomy and parathyroidectomy. Online registration is available at: http://www.mastersinendocrine.com Friday,... Continue reading

ITOG Remembers Jean Vicks

Jean G. Vicks passed away on April 5, 2013 after her fourteen year battle with medullary thyroid cancer (MTC).  She was 49.  The diagnosis of MTC in 1999 resulted in seven surgeries, two clinical trials and three additional chemotherapy regimens in her desire to be well.  Jean was honored as the inspiration for ITOG at the ITOG Annual Meeting at the Mayo Clinic in April.  Jean’s grace, selflessness and enthusiasm in the face of overwhelming challenges are an inspiration to all who knew her. When Jean was diagnosed, she made a goal to live long enough to see her children begin college.  Jean... Continue reading

TA Associates Realty Selects ITOG as Charitable Beneficiary

TA Associates Realty is one of the leading investors in commercial real estate in the United States.  Michael Ruane, a founding member of TA Associates Realty, created an event to provide a valuable business gathering, golf at exceptional courses and raise funds to donate to worthy charities selected by the TA Associates team.  ITOG was selected as the 2013 Charitable Beneficiary for the event held on July 29th.  The day began with an informative business forum including a round table of leading executives from across the country.  After lunch, participants played the historic Blue Hill... Continue reading

16th International Thyroid Cancer Survivors’ Conference

October 9, 2013 The 16th annual International Thyroid Cancer Survivors’ www.ThyCa.org conference took place from September 27-29, 2013 in Philadelphia. A record breaking 550 attendees came to the meeting. Through this conference, ThyCa is able to bring together the latest research, advances in treatment, follow-up and coping skills for the well-being of thyroid cancer survivors and their caregivers. Dr. Steven Sherman, Dr. Lori Wirth and Dwight Vicks, ITOG board members, led two sessions in the conference.  The sessions, Learn about the International... Continue reading

Sorafenib Improves Thyroid Cancer Outcomes

(ASCO, June 2, 2013) A large phase III clinical trial reported that sorafenib improves progression free survival for patients with radioactive iodine refractory, differentiated thyroid cancer. June 2, 2013 marks a major milestone in thyroid cancer, as ITOG member Marcia Brose, MD, PhD, Assistant Professor of Medicine, Hematology/Oncology and of Otolaryngology and Head and Neck Surgery in the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania in Philadelphia, presented the results from the DECISION trial, the first randomized, phase III clinical trial of... Continue reading

Medullary thyroid cancer : Mutations predict response to oral chemotherapy

For advanced non-resectable MTC (medullary thyroid cancer), there are now two FDA-approved drugs, vandetanib (Caprelsa) and cabozantinib (Cometriq).  At the 2013 American Society of Clinical Oncology meeting in Chicago, ITOG investigators working with Exelixis, Inc. reported a major study of the impact of different gene mutations in MTC tumors on responses to cabozantinib.  Using a large data set from the Phase III clinical trial that led to the approval of the drug earlier this year, the investigators retrospectively studied several key DNA mutations identified in previous studies of MTC... Continue reading

ITOG Annual Meeting 2013

ITOG held its 2013 Annual Meeting in Rochester, Minnesota at Mayo Medical Center on April 28-30th.  The meeting was hosted by Drs. Keith Bible and Robert Smallridge.  Highlights from the meeting included scientific sessions on Molecular Therapeutic Approaches to Thyroid Cancer.  Dr. Steve Russell outlined his program for developing oncolytic viruses and described the efforts to bring these to the clinic.  ITOG members had an orientation and overview of ACCRU, which included tours of Mayo/ACCRU research laboratories and specimen handling/archiving facilities.  Scientific sessions included... Continue reading

ITOG Opens First Clinical Trial

ITOG is poised to open it’s first clinical trial for treatment of differentiated thyroid cancer. This multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University, will examine whether patients who had progression of their thyroid cancer on a VEGR inhibitor benefit from treatment with Cabozantinib.NCI9312/OSU12154/RU241210I is an investigator-initiated, multicenter, open label, phase II trial of Cabozantinib in patients with radioiodine-refractory, differentiated thyroid cancer (DTC), who progressed on first-line therapy with a VEGFR antagonist. ITOG’s first... Continue reading

ITOG Membership Doubles in 2012

December, 2012. The International Thyroid Oncology Group (ITOG) has completed a major period of membership expansion, doubling its membership. ITOG members hail from 29 leading academic medical institutions on three continents. ITOG counts numerous leading European thyroid specialists among its membership. ITOG members are drawn from every aspect of clinical, pathological, and scientific disciplines to assemble a “dream-team” of specialists for thyroid cancer. ITOG members are united by the belief that working together is the only way to catalyze a cure for thyroid cancer.

Pages

Contact

International Thyroid Oncology Group
5166 Commercial Drive
Yorkville, New York 13495